{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:10:35Z","timestamp":1793725835860,"version":"4.6.1"},"reference-count":312,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.phrs.2024.107544","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T08:03:21Z","timestamp":1733904201000},"page":"107544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment"],"prefix":"10.1016","volume":"211","author":[{"given":"Cristina","family":"Camps-Fajol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Cavero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Minguill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Surrall\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107544_bib1","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0708078105","article-title":"Estimating the size of the human interactome","volume":"105","author":"Stumpf","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.1280","article-title":"An empirical framework for binary interactome mapping","volume":"6","author":"Venkatesan","year":"2009","journal-title":"Nat. Methods"},{"key":"10.1016\/j.phrs.2024.107544_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2011.02.016","article-title":"Interactome networks and human disease","volume":"144","author":"Vidal","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib4","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1126\/science.abj6987","article-title":"The complete sequence of a human genome","volume":"376","author":"Nurk","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107544_bib5","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000641","article-title":"Protein - protein interactions as targets for small-molecule therapeutics in cancer","volume":"10","author":"White","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.phrs.2024.107544_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2008.151","article-title":"Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles","volume":"34","author":"Blazer","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2024.107544_bib7","article-title":"Identification of immune-associated genes in diagnosing aortic valve calcification with metabolic syndrome by integrated bioinformatics analysis and machine learning","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2024.107544_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27113470","article-title":"Transcriptome profiling of HCT-116 colorectal cancer cells with RNA sequencing reveals novel targets for polyphenol nano curcumin","volume":"27","author":"Azeez","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2024.107544_bib9","article-title":"Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations","volume":"63","author":"Coulson","year":"2014","journal-title":"West Indian Med. J."},{"key":"10.1016\/j.phrs.2024.107544_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-019-00542-8","article-title":"Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies","volume":"14","author":"Torka","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.phrs.2024.107544_bib11","article-title":"Recent advances in the development of protein\u2013protein interactions modulators: mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2008.03.009","article-title":"Peptidomimetics, a synthetic tool of drug discovery","volume":"12","author":"Vagner","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib13","article-title":"Stapled peptides inhibitors: a new window for target drug discovery","volume":"17","author":"Ali","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.phrs.2024.107544_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2024.107544_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107544_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2024.107544_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-017-9717-6","article-title":"RNA interference-based therapy and its delivery systems","volume":"37","author":"Chen","year":"2018","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.phrs.2024.107544_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.644718","article-title":"Insight into the prospects for RNAi therapy of cancer","volume":"12","author":"Tian","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2024.107544_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2014.01.004","article-title":"HTS assays for developing the molecular pharmacology of ion channels","volume":"15","author":"McManus","year":"2014","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.phrs.2024.107544_bib21","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107544_bib22","doi-asserted-by":"crossref","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?","author":"Sriram","year":"2018","journal-title":": Mol. Pharm."},{"key":"10.1016\/j.phrs.2024.107544_bib23","article-title":"Rational design of peptide-based inhibitors disrupting protein-protein interactions","volume":"9","author":"Wang","year":"2021","journal-title":"Front Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/17460441.2018.1430763","article-title":"Hot-spot analysis for drug discovery targeting protein-protein interactions","volume":"13","author":"Rosell","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107544_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbiomolbio.2015.01.009","article-title":"Flexibility and small pockets at protein-protein interfaces: new insights into druggability","volume":"119","author":"Jubb","year":"2015","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib26","article-title":"Hydrophobic complementarity in protein-protein docking","volume":"56","author":"Berchanski","year":"2004","journal-title":"Protein.\u00a0Struct.\u00a0Funct. Genet."},{"key":"10.1016\/j.phrs.2024.107544_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2007.10.005","article-title":"Drug discovery beyond the \u201crule-of-five\u201d","volume":"18","author":"Zhang","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.phrs.2024.107544_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/iub.383","article-title":"Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations","volume":"62","author":"Buchwald","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.phrs.2024.107544_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/nature06526","article-title":"Reaching for high-hanging fruit in drug discovery at protein-protein interfaces","volume":"450","author":"Wells","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107544_bib30","doi-asserted-by":"crossref","DOI":"10.1021\/ci300175u","article-title":"Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces","volume":"52","author":"Zerbe","year":"2012","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.phrs.2024.107544_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002951","article-title":"Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface","volume":"9","author":"Johnson","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/17.3.284","article-title":"ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions","volume":"17","author":"Thorn","year":"2001","journal-title":"Bioinformatics"},{"key":"10.1016\/j.phrs.2024.107544_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031550","article-title":"Challenges in discovering drugs that target the protein\u2013protein interactions of disordered proteins","volume":"23","author":"Ol\u00e1h","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107544_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s12915-017-0446-7","article-title":"A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53","volume":"15","author":"Wong","year":"2017","journal-title":"BMC Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-016-0223-x","article-title":"Advancement and applications of peptide phage display technology in biomedical science","volume":"23","author":"Wu","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.phrs.2024.107544_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2009.05.006","article-title":"A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the ras oncogene","volume":"137","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-1562-1_6","article-title":"Analysis of protein-protein interactions by protein microarrays","author":"Montero-Calle","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-41448-5_18","article-title":"Protein-protein interaction detection via mass spectrometry-based proteomics","author":"Turriziani","year":"2016","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib39","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20188792","article-title":"Mass spectrometry-based protein\u2013protein interaction networks for the study of human diseases","volume":"17","author":"Richards","year":"2021","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsb.2020.107662","article-title":"A biophysical and structural analysis of the interaction of BLNK with 14-3-3 proteins","volume":"212","author":"Soini","year":"2020","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00098","article-title":"Bio-layer interferometry analysis of the target binding activity of CRISPR-cas effector complexes","volume":"7","author":"M\u00fcller-Esparza","year":"2020","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.phrs.2024.107544_bib42","article-title":"Surface plasmon resonance sensing of biorecognition interactions within the tumor suppressor P53 network","volume":"17","author":"Moscetti","year":"2017","journal-title":"Sens. (Switz. )"},{"key":"10.1016\/j.phrs.2024.107544_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2006.02.011","article-title":"Dual polarization interferometry characterization of carbohydrate-protein interactions","volume":"352","author":"Ricard-Blum","year":"2006","journal-title":"Anal. Biochem"},{"key":"10.1016\/j.phrs.2024.107544_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-9678-0_2","article-title":"Light scattering to quantify protein\u2013protein interactions at high protein concentrations","author":"Woldeyes","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib45","doi-asserted-by":"crossref","unstructured":"N.J. GreenfieldCircular dichroism (CD) analyses of protein-protein interactions, in: Protein-Protein Interactions: Methods and Applications2015, https:\/\/doi.org\/10.1007\/978-1-4939-2425-7_15.","DOI":"10.1007\/978-1-4939-2425-7_15"},{"key":"10.1016\/j.phrs.2024.107544_bib46","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1021\/cr400698c","article-title":"Modulators of protein-protein interactions","volume":"114","author":"Milroy","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2024.107544_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/mas.21574","article-title":"Discovering cellular protein-protein interactions: technological strategies and opportunities","volume":"38","author":"Titeca","year":"2019","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.phrs.2024.107544_bib48","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.biophys.37.032807.125842","article-title":"Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells","volume":"37","author":"Kerppola","year":"2008","journal-title":"Annu Rev. Biophys."},{"key":"10.1016\/j.phrs.2024.107544_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007449","article-title":"Ten quick tips for homology modeling of high-resolution protein 3D structures","volume":"16","author":"Haddad","year":"2020","journal-title":"PLoS Comput. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107544_bib50","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1042\/BST0361438","article-title":"Crystallography and protein\u2013protein interactions: biological interfaces and crystal contacts","volume":"36","author":"Kobe","year":"2008","journal-title":"Biochem Soc. Trans. 1"},{"key":"10.1016\/j.phrs.2024.107544_bib51","series-title":"Protein-Protein Interactions. Methods in Molecular Biology","article-title":"Protein-protein interaction analysis by nuclear magnetic resonance spectroscopy","author":"Gao","year":"2004"},{"issue":"4","key":"10.1016\/j.phrs.2024.107544_bib52","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1080\/02648725.2023.2168912","article-title":"Deciphering sperm functions using biological networks","volume":"40","author":"Kutchy","year":"2023","journal-title":"Biotechnol. Genet. Eng. Rev."},{"issue":"6","key":"10.1016\/j.phrs.2024.107544_bib53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/1389202911314060004","article-title":"Computational prediction of protein-protein interaction networks: algo-rithms and resources","volume":"14","author":"Zahiri","year":"2013","journal-title":"Curr. Genom."},{"issue":"7","key":"10.1016\/j.phrs.2024.107544_bib54","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1021\/acs.chemrev.3c00550","volume":"124","author":"Grassmann","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2024.107544_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.32604\/biocell.2024.049891","article-title":"Computational and bioinformatics tools for understanding disease mechanisms","volume":"48","author":"Athar","year":"2024","journal-title":"Biocell"},{"key":"10.1016\/j.phrs.2024.107544_bib56","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1038\/s41598-022-12105-8","article-title":"Structure-based assessment and druggability classification of protein\u2013protein interaction sites","volume":"12","author":"Alzyoud","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107544_bib57","doi-asserted-by":"crossref","first-page":"W387","DOI":"10.1093\/nar\/gks336","article-title":"PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure","author":"Koes","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.phrs.2024.107544_bib58","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acs.jcim.1c00204","article-title":"Finding druggable sites in proteins using TACTICS","volume":"61","author":"Evans","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.phrs.2024.107544_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/nature11503","article-title":"Structure-based prediction of protein-protein interactions on a genome-wide scale","volume":"490","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107544_bib60","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science (1979)"},{"key":"10.1016\/j.phrs.2024.107544_bib61","doi-asserted-by":"crossref","DOI":"10.1021\/ja050122x","article-title":"Terphenyl-based Bak BH3 \u03b1-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL","volume":"127","author":"Yin","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2024.107544_bib62","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-04-0342","article-title":"p53 \u03b1-helix mimetics antagonize p53\/MDM2 interaction and activate p53","volume":"4","author":"Chen","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib63","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.9b01295","article-title":"Discovery of a potent and selective oral inhibitor of ERK1\/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of nonsmall cell lung cancer (NSCLC)","volume":"62","author":"Ward","year":"2019","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib64","doi-asserted-by":"crossref","DOI":"10.1021\/jm070091b","article-title":"Identification of inhibitors of protein kinase B using fragment-based lead discovery","volume":"50","author":"Saxty","year":"2007","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib65","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-0700","article-title":"First-in-human study of AT13148, a Dual ROCK-AKT inhibitor in patients with solid tumors","volume":"26","author":"McLeod","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107544_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3690","article-title":"Oncogenic protein interfaces: small molecules, big challenges","volume":"14","author":"Nero","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112764","article-title":"Computational methods-guided design of modulators targeting protein-protein interactions (PPIs)","volume":"207","author":"Qiu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24234309","article-title":"Concepts and core principles of fragment-based drug design","volume":"24","author":"Kirsch","year":"2019","journal-title":"Molecules"},{"issue":"2013","key":"10.1016\/j.phrs.2024.107544_bib70","first-page":"bat039","article-title":"TIMBAL v2: update of a database holding small molecules modulating protein-protein interactions","volume":"13","author":"Higueruelo","year":"2013","journal-title":"Database (Oxf.)"},{"issue":"19-20","key":"10.1016\/j.phrs.2024.107544_bib71","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.drudis.2013.05.003","article-title":"iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions","volume":"18","author":"Labb\u00e9","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2024.107544_bib72","article-title":"2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein-protein interactions","author":"Basse","year":"2016","journal-title":"Database.\u00a0J. Biol. Database. Curation"},{"issue":"6","key":"10.1016\/j.phrs.2024.107544_bib73","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1021\/acschembio.0c00179","article-title":"Fr-PPIChem: an academic compound library dedicated to protein-protein interactions","volume":"15","author":"Bosc","year":"2020","journal-title":"ACS Chem. Biol."},{"issue":"22","key":"10.1016\/j.phrs.2024.107544_bib74","doi-asserted-by":"crossref","first-page":"7986","DOI":"10.3390\/molecules27227986","article-title":"Machine learning models to predict protein\u2013protein interaction inhibitors","volume":"27","author":"D\u00edaz-Eufracio","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.phrs.2024.107544_bib75","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.drudis.2018.11.013","article-title":"Analysis of solvent-exposed and buried co-crystallized ligands: a case study to support the design of novel protein-protein interaction inhibitors","volume":"24","author":"Trisciuzzi","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2024.107544_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011403","article-title":"Protein-protein interaction antagonists as novel inhibitors of non-canonical polyubiquitylation","volume":"5","author":"Scheper","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107544_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/07391102.2020.1835714","article-title":"In silico identification of small molecule modulators for disruption of Hsp90\u2013Cdc37 protein\u2013protein interaction interface for cancer therapeutic application","volume":"40","author":"Dike","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.phrs.2024.107544_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2009.04.124","article-title":"Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking","volume":"19","author":"Lawrence","year":"2009","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107544_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2024.107544_bib80","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026062","article-title":"Tumor-suppressor functions of the TP53 pathway","volume":"6","author":"Aubrey","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.phrs.2024.107544_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy","volume":"49","author":"Shangary","year":"2009","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"10.1016\/j.phrs.2024.107544_bib83","doi-asserted-by":"crossref","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib84","doi-asserted-by":"crossref","DOI":"10.2147\/DDDT.S182444","article-title":"Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening","volume":"12","author":"Atatreh","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib85","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/ml4000657","article-title":"Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development","volume":"4","author":"Vu","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107544_bib86","article-title":"Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2024.107544_bib87","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9559","article-title":"A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs","volume":"41","author":"Shaheen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib88","doi-asserted-by":"crossref","DOI":"10.4161\/cc.8.8.8185","article-title":"High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx","volume":"8","author":"Czarna","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phrs.2024.107544_bib89","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0508476103","article-title":"Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo","volume":"103","author":"Francoz","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib90","doi-asserted-by":"crossref","DOI":"10.1021\/co500026b","article-title":"Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor","volume":"16","author":"Boltjes","year":"2014","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.phrs.2024.107544_bib91","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M109.073056","article-title":"Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX","volume":"285","author":"Phan","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2010.10.024","article-title":"A stapled p53 helix overcomes HDMX-mediated suppression of p53","volume":"18","author":"Bernal","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib93","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled \u03b1-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy","volume":"110","author":"Chang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2020.04.011","article-title":"Identification of a structural determinant for selective targeting of HDMX","volume":"28","author":"Ben-Nun","year":"2020","journal-title":"Structure"},{"key":"10.1016\/j.phrs.2024.107544_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao3003","article-title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","volume":"10","author":"Carvajal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2024.107544_bib96","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-1741","article-title":"Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity","volume":"11","author":"Zhou","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2024.107544_bib97","article-title":"Structure-Based Discovery of MDM2\/4 dual inhibitors that exert antitumor activities against MDM4-overexpressing cancer cells","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib98","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06498","article-title":"A distinct p53 target gene set predicts for response to the selective p53- HDM2 inhibitor NVP-CGM097","volume":"4","author":"Jeay","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2024.107544_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibs.2013.12.006","article-title":"Many players in BCL-2 family affairs","volume":"39","author":"Moldoveanu","year":"2014","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.phrs.2024.107544_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.02.026","article-title":"BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation","volume":"165","author":"Llambi","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2003.08.012","article-title":"Structural biology of the Bcl-2 family of proteins","volume":"1644","author":"Petros","year":"2004","journal-title":"Biochim Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.phrs.2024.107544_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2012.88","article-title":"Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia","volume":"26","author":"Billard","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2024.107544_bib103","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib106","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib107","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2021-0140","article-title":"A Phase i study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors","volume":"17","author":"Puglisi","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib108","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2024.107544_bib109","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2020.1845332","article-title":"Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study","volume":"62","author":"de Vos","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2024.107544_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2024.107544_bib111","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib112","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.68.4.2521-2528.1994","article-title":"An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys\/His sequence motifs","volume":"68","author":"Birnbaum","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2024.107544_bib113","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.8b01668","article-title":"Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives","volume":"62","author":"Cong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/S1097-2765(03)00054-6","article-title":"Mechanism of XIAP-mediated inhibition of caspase-9","volume":"11","author":"Shiozaki","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib115","doi-asserted-by":"crossref","DOI":"10.1038\/35050012","article-title":"Structural basis of IAP recognition by Smac\/DIABLO","volume":"408","author":"Wu","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107544_bib116","doi-asserted-by":"crossref","DOI":"10.1021\/jm300060k","article-title":"Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)","volume":"55","author":"Flygare","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib117","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-0308","article-title":"A phase i dose-escalation study evaluating the safety tolerability and pharmacokinetics of CUDC-427, a potent, oral, monovalent IAP antagonist, in patients with refractory solid tumors","author":"Tolcher","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib118","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3621","article-title":"Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed\/refractory metastatic colorectal cancer","volume":"31","author":"Senzer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib119","doi-asserted-by":"crossref","DOI":"10.1021\/jm101505d","article-title":"A potent and orally active antagonist (SM-406\/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment","volume":"54","author":"Cai","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2022.12.015","article-title":"Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial","volume":"183","author":"TAO","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib121","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1021\/acs.jmedchem.5b00706","article-title":"Fragment-based drug discovery targeting inhibitor of apoptosis proteins: discovery of a non-alanine lead series with dual activity against cIAP1 and XIAP","volume":"58","author":"Chessari","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib122","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-17-0848","article-title":"ASTX660, a novel non-peptidomimetic antagonist of cIAP1\/2 and XIAP, potently induces TNF\u03b1-dependent apoptosis in cancer cell lines and inhibits tumor growth","volume":"17","author":"Ward","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib123","doi-asserted-by":"crossref","first-page":"7314","DOI":"10.1021\/acs.jmedchem.8b00900","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib124","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-19-1430","article-title":"A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma","volume":"26","author":"Mita","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/348166a0","article-title":"Reduced levels of hsp90 compromise steroid receptor action in vivo","volume":"348","author":"Picard","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107544_bib126","article-title":"hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures","volume":"9","author":"Borkovich","year":"1989","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib127","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0902626106","article-title":"An essential role for ATP binding and hydrolysis in the chaperone activity of GRP94 in cells","volume":"106","author":"Ostrovsky","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib128","article-title":"Hsp90 isoforms: functions, expression and clinical importance","volume":"562","author":"Sreedhar","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2024.107544_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2007.07.036","article-title":"Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches","volume":"131","author":"McClellan","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib130","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-06-4511","article-title":"High HSP90 expression is associated with decreased survival in breast cancer","volume":"67","author":"Pick","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib131","article-title":"High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer","volume":"2019","author":"Zhang","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.phrs.2024.107544_bib132","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M512613200","article-title":"Hsp90 recognizes a common surface on client kinases","volume":"281","author":"Citri","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib133","article-title":"The Hsp90 molecular chaperone: an open and shut case for treatment","volume":"410","author":"Pearl","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2024.107544_bib134","doi-asserted-by":"crossref","DOI":"10.2174\/1381612811306030347","article-title":"The therapeutic target Hsp90 and cancer hallmarks","volume":"19","author":"Miyata","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2024.107544_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2004.03.033","article-title":"Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms","volume":"11","author":"Wright","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib136","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-05959-3","article-title":"Structural dynamics of RAF1-HSP90-CDC37 and HSP90 complexes reveal asymmetric client interactions and key structural elements","volume":"7","author":"Finci","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2011.01.029","article-title":"Substrate binding drives large-scale conformational changes in the hsp90 molecular chaperone","volume":"42","author":"Street","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib138","article-title":"Dynamics revelation of conformational changes and binding modes of heat shock protein 90 induced by inhibitor associations","volume":"8","author":"Chen","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.phrs.2024.107544_bib139","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c01715","article-title":"Thermodynamic dissection of potency and selectivity of cytosolic Hsp90 inhibitors","volume":"64","author":"Yoshimura","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib140","doi-asserted-by":"crossref","DOI":"10.1007\/BF00689048","article-title":"Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent","volume":"36","author":"Supko","year":"1995","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.phrs.2024.107544_bib141","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-11-0562","article-title":"The novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations","volume":"17","author":"Floris","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2011.10.008","article-title":"Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers","volume":"1823","author":"Jhaveri","year":"2012","journal-title":"Biochim Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.phrs.2024.107544_bib143","series-title":"Adv Cancer Res.","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/bs.acr.2015.12.001","article-title":"Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects","author":"Garg","year":"2016"},{"key":"10.1016\/j.phrs.2024.107544_bib144","first-page":"4177","article-title":"Chemoproteomics-driven drug discovery: identification of novel hsp90 inhibitors","volume":"67","author":"Hall","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib145","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-08-0758","article-title":"BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90","volume":"8","author":"Lundgren","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib146","article-title":"Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90-binding agents","volume":"6","author":"Bagatell","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib147","article-title":"Redefining the phenotype of heat shock protein 90 (Hsp90) inhibitors","volume":"23","author":"Wang","year":"2017","journal-title":"Chem. - A Eur. J."},{"key":"10.1016\/j.phrs.2024.107544_bib148","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14902-y","article-title":"Discovery of new molecular entities able to strongly interfere with Hsp90C-terminal domain","volume":"8","author":"Terracciano","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107544_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(12)72089-0","article-title":"291 TAS-116, a novel, orally bioavailable HSP90a\/\u03b2 selective inhibitor demonstrates highly potent antitumor activity in preclinical models with a favorable PK profile","volume":"48","author":"Ohkubo","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(12)72088-9","article-title":"290 TAS-116, a novel, orally bioavailable highly potent HSP90a\/\u03b2 selective inhibitor demonstrates favorable tissue distribution properties which lead to minimized ocular toxicity","volume":"48","author":"Kodama","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib151","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-14-0219","article-title":"TAS-116, a highly selective inhibitor of heat shock protein 90\u03b1 and \u03b2, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models","volume":"14","author":"Ohkubo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib152","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.11524","volume":"39","author":"Honma","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib153","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M003701200","article-title":"The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone","volume":"275","author":"Marcu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib154","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M512406200","article-title":"Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization","volume":"281","author":"Allan","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib155","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib156","article-title":"STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis article","volume":"24","author":"Priego","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2024.107544_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110645","article-title":"Revisiting silibinin as a novobiocin-like Hsp90\u00a0C-terminal inhibitor: computational modeling and experimental validation","volume":"132","author":"Cuy\u00e0s","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.phrs.2024.107544_bib158","doi-asserted-by":"crossref","DOI":"10.1038\/nrc2420","article-title":"Targeting the oncogene and kinome chaperone CDC37","volume":"8","author":"Gray","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2012.06.047","article-title":"Quantitative analysis of Hsp90-client interactions reveals principles of substrate recognition","volume":"150","author":"Taipale","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(03)01027-4","article-title":"The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50cdc37","volume":"116","author":"Roe","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2018.07.012","article-title":"DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction","volume":"434","author":"Chen","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2024.107544_bib162","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax2277","article-title":"Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer","volume":"5","author":"Wang","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2024.107544_bib163","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-07-0484","article-title":"A novel Hsp90 inhibitor to disrupt Hsp90\/Cdc37 complex against pancreatic cancer cells","volume":"7","author":"Zhang","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2009.09.017","article-title":"Withaferin A targets heat shock protein 90 in pancreatic cancer cells","volume":"79","author":"Yu","year":"2010","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.phrs.2024.107544_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2011.11.004","article-title":"Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50Cdc37 complex and direct interactions with amino acids residues of Hsp90","volume":"23","author":"Li","year":"2012","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.phrs.2024.107544_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib167","article-title":"Mammalian MYC proteins and cancer","volume":"2014","author":"Tansey","year":"2014","journal-title":"N. J. Sci."},{"key":"10.1016\/j.phrs.2024.107544_bib168","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2008.111","article-title":"Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis","volume":"21","author":"Gurel","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.phrs.2024.107544_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040883","article-title":"Blocking myc to treat cancer: reflecting on two decades of omomyc","volume":"9","author":"Mass\u00f3-Vall\u00e9s","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2024.107544_bib170","doi-asserted-by":"crossref","DOI":"10.1101\/gad.6.2.166","article-title":"Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc\/Max heterodimers","volume":"6","author":"Berberich","year":"1992","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2024.107544_bib171","doi-asserted-by":"crossref","DOI":"10.1038\/sj.onc.1200948","article-title":"Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells","volume":"14","author":"Ca\u00f1elles","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2024.107544_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/S0969-2126(97)00207-4","article-title":"The crystal structure of an intact human Max-DNA complex: new insights into mechanisms of transcriptional control","volume":"5","author":"Brownlie","year":"1997","journal-title":"Structure"},{"key":"10.1016\/j.phrs.2024.107544_bib173","doi-asserted-by":"crossref","DOI":"10.1038\/sj.onc.1202199","article-title":"Design and properties of a Myc derivative that efficiently homodimerizes","volume":"17","author":"Soucek","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2024.107544_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(02)01284-9","article-title":"X-ray structures of Myc-Max and Mad-Max recognizing DNA: molecular bases of regulation by proto-oncogenic transcription factors","volume":"112","author":"Nair","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib175","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202103090","article-title":"The long journey to bring a myc inhibitor to the clinic","volume":"220","author":"Whitfield","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib176","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.201402189","article-title":"Discovery of methyl 4\u2019-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1\u2019-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization","volume":"9","author":"Chauhan","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2024.107544_bib177","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju320","article-title":"Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer","volume":"106","author":"Stellas","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2024.107544_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib179","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-022-06673-6","article-title":"MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975","volume":"195","author":"Tang","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2024.107544_bib180","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3390\/cancers12092582","article-title":"Isolation and characterization of two novel colorectal cancer cell lines, containing a subpopulation with potential stem-like properties: treatment options by MYC\/NMYC inhibition","volume":"12","author":"Schulte am Esch","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107544_bib181","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051024","article-title":"Novel primary human cancer stem-like cell populations from non-small cell lung cancer: inhibition of cell survival by targeting nf-\u03bab and myc signaling","volume":"10","author":"Windm\u00f6ller","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2024.107544_bib182","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112916","article-title":"Suppression of pi3k\/akt\/mtor\/c-myc\/mtp53 positive feedback loop induces cell cycle arrest by dual pi3k\/mtor inhibitor pqr309 in endometrial cancer cell lines","volume":"10","author":"Hsin","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2024.107544_bib183","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28107-4","article-title":"A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation","volume":"8","author":"Castell","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107544_bib184","article-title":"The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells","volume":"39","author":"AlSultan","year":"2021","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.phrs.2024.107544_bib185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022284","article-title":"The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy","volume":"6","author":"Savino","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107544_bib186","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00248-19","article-title":"Omomyc reveals new mechanisms to inhibit the MYC oncogene","volume":"39","author":"Demma","year":"2019","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2024.107544_bib188","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8826","article-title":"Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation","volume":"7","author":"Fiorentino","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2024.107544_bib189","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5012","article-title":"Intrinsic cell-penetrating activity propels omomyc from proof of concept to viable anti-myc therapy","volume":"11","author":"Beaulieu","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2024.107544_bib190","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2024.107544_bib191","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib192","article-title":"Meaningful relationships: the regulation of the Ras\/Raf\/MEK\/ERK pathway by protein interactions","volume":"351","author":"Kolch","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2024.107544_bib193","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107544_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/genes12071094","article-title":"The importance of being PI3K in the RAS signaling network","volume":"12","author":"Cuesta","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.phrs.2024.107544_bib195","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.23687","article-title":"Implications of mitogen-activated protein kinase signaling in glioma","volume":"94","author":"Pandey","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.phrs.2024.107544_bib196","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208255119","article-title":"Hyper-active RAS\/MAPK introduces cancer-specific mitotic vulnerabilities","volume":"119","author":"Herman","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib197","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Hum. Genom."},{"key":"10.1016\/j.phrs.2024.107544_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2021.02.014","article-title":"Targeting son of sevenless 1: the pacemaker of KRAS","volume":"62","author":"Kessler","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib199","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who\u2019s the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2024.107544_bib200","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2024.107544_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib202","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib203","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.7b01243","article-title":"Structural biology-inspired discovery of novel KRAS-PDE\u03b4 inhibitors","volume":"60","author":"Jiang","year":"2017","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib204","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib205","doi-asserted-by":"crossref","DOI":"10.1177\/1947601911408078","article-title":"Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives","volume":"2","author":"Rojas","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188445","article-title":"SOS GEFs in health and disease","volume":"1874","author":"Baltan\u00e1s","year":"2020","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib207","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c00741","article-title":"Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein-protein interaction","volume":"65","author":"Ketcham","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(03)00149-1","article-title":"Structural evidence for feedback activation by Ras\u00b7GTP of the Ras-specific nucleotide exchange factor SOS","volume":"112","author":"Margarit","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib209","article-title":"Mechanism of SOS PR-domain autoinhibition revealed by single-molecule assays on native protein from lysate","volume":"8","author":"Lee","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2024.107544_bib210","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.9b10710","article-title":"High-affinity interactions of the nSH3\/cSH3 domains of Grb2 with the C-terminal proline-rich domain of SOS1","volume":"142","author":"Liao","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2024.107544_bib211","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122531119","article-title":"A two-component protein condensate of the EGFR cytoplasmic tail and Grb2 regulates Ras activation by SOS at the membrane","volume":"119","author":"Lin","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2004.10.005","article-title":"Structural analysis of autoinhibition in the Ras activator son of sevenless","volume":"119","author":"Sondermann","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib213","article-title":"Membrane-dependent signal integration by the Ras activator Son of sevenless","volume":"15","author":"Gureasko","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib214","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.612","article-title":"An orthosteric inhibitor of the Ras-Sos interaction","volume":"7","author":"Patgiri","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib215","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1413185112","article-title":"Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices","volume":"112","author":"Leshchiner","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib216","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1116510109","article-title":"Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity","volume":"109","author":"Maurer","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib217","doi-asserted-by":"crossref","DOI":"10.1002\/anie.201201358","article-title":"Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation","volume":"51","author":"Sun","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.phrs.2024.107544_bib218","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1315798111","article-title":"Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange","volume":"111","author":"Burns","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib219","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-17-0666","article-title":"Small molecule\u2013mediated activation of ras elicits biphasic modulation of phospho-erk levels that are regulated through negative feedback on sos1","volume":"17","author":"Howes","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107544_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2018.01.025","article-title":"High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling","volume":"548","author":"Burns","year":"2018","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.phrs.2024.107544_bib221","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.8b00360","article-title":"Discovery of aminopiperidine indoles that activate the guanine nucleotide exchange factor SOS1 and modulate RAS signaling","volume":"61","author":"Abbott","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib222","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.8b01108","article-title":"Discovery and structure-based optimization of benzimidazole-derived activators of SOS1-mediated nucleotide exchange on RAS","volume":"61","author":"Hodges","year":"2018","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib223","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00511","article-title":"Discovery of sulfonamide-derived agonists of SOS1-mediated nucleotide exchange on RAS using fragment-based methods","volume":"63","author":"Sarkar","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib224","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS\u2013SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107544_bib225","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2021.02.002","article-title":"KRAS G12C\u2013mutant non\u2013small cell lung cancer: biology, developmental therapeutics, and molecular testing","volume":"23","author":"Veluswamy","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.phrs.2024.107544_bib227","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib228","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c01949","article-title":"One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS","volume":"64","author":"Ramharter","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib229","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"Bi-3406, a potent and selective sos1\u2013kras interaction inhibitor, is effective in kras-driven cancers through combined mek inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2024.107544_bib230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3651","article-title":"A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors","volume":"38","author":"Gort","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib231","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2024.107544_bib232","doi-asserted-by":"crossref","DOI":"10.1021\/acsomega.1c00681","article-title":"Discovery of novel CCR5 ligands as anticolorectal cancer agents by sequential virtual screening","volume":"6","author":"El-Zohairy","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.phrs.2024.107544_bib233","article-title":"Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2024.107544_bib234","doi-asserted-by":"crossref","DOI":"10.1038\/ni1191","article-title":"T cell costimulation by chemokine receptors","volume":"6","author":"Molon","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2024.107544_bib235","doi-asserted-by":"crossref","DOI":"10.1002\/pros.20306","article-title":"Expression of CCL5 (RANTES) and CCR5 in prostate cancer","volume":"66","author":"Vaday","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.phrs.2024.107544_bib236","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-11-3917","article-title":"CCR5 antagonist blocks metastasis of basal breast cancer cells","volume":"72","author":"Velasco-Vel\u00e1zquez","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib237","article-title":"CCR5\/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells","volume":"8","author":"Singh","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107544_bib238","article-title":"Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma","volume":"59","author":"Luboshits","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib239","article-title":"Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor","volume":"39","author":"Kim","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2006.01.029","article-title":"Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder","volume":"102","author":"Tsukishiro","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib241","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.23401","article-title":"Gastric cancer cells exploit CD4+\u2009cell-derived CCL5 for their growth and prevention of CD8+\u2009cell-involved tumor elimination","volume":"122","author":"Sugasawa","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib242","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2020.01.009","article-title":"The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction","volume":"474","author":"Huang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2024.107544_bib243","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02300-w","article-title":"Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling","volume":"41","author":"Gao","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib244","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028842","article-title":"CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFR\u03b2 in colorectal carcinoma","volume":"6","author":"Cambien","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107544_bib245","doi-asserted-by":"crossref","DOI":"10.1007\/s13402-018-0415-3","article-title":"CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer","volume":"42","author":"Pervaiz","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib246","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-020-03382-9","article-title":"Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis","volume":"147","author":"Pervaiz","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib247","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1150398","article-title":"Maraviroc decreases CCL8-mediated migration of CCR5+\u2009regulatory T cells and reduces metastatic tumor growth in the lungs","volume":"5","author":"Halvorsen","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.phrs.2024.107544_bib248","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-015-0607-x","article-title":"CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells","volume":"32","author":"Pervaiz","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib249","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-17-0915","article-title":"CCR5 Governs DNA damage repair and breast cancer stem cell expansion","volume":"78","author":"Jiao","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib250","article-title":"In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability","volume":"107","author":"Casagrande","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2024.107544_bib251","doi-asserted-by":"crossref","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2024.107544_bib252","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194935","article-title":"Maraviroc prevents hcc development by suppressing macrophages and the liver progenitor cell response in a murine chronic liver disease model","volume":"13","author":"Passman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107544_bib253","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2024.107544_bib254","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P5-17-08","article-title":"Abstract P5-17-08: a phase Ib\/II study of leronlimab combined with carboplatin in patients with CCR5+\u2009metastatic triple-negative breast cancer (mTNBC)","volume":"82","author":"Cristofanilli","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2022.03.017","article-title":"Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer \u2013 the PICCASSO phase I trial","volume":"167","author":"Haag","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.clcc.2024.05.003","article-title":"Safety and efficacy of vicriviroc (MK-7690) in combination with pembrolizumab in patients with advanced or metastatic microsatellite stable colorectal cancer","author":"Bessudo","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.phrs.2024.107544_bib257","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032864","article-title":"Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study","volume":"7","author":"Kothandan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107544_bib258","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-6-45","article-title":"Genomic organization, annotation, and ligand-receptor inferences of chicken chemokines and chemokine receptor genes based on comparative genomics","volume":"6","author":"Wang","year":"2005","journal-title":"BMC Genom."},{"key":"10.1016\/j.phrs.2024.107544_bib259","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-019-03255-6","article-title":"Dual CCR5\/CCR2 targeting: opportunities for the cure of complex disorders","volume":"76","author":"Fantuzzi","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.phrs.2024.107544_bib260","doi-asserted-by":"crossref","first-page":"28697","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2024.107544_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119034","article-title":"Role of CCL2\/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: latest evidence and therapeutic approaches","volume":"269","author":"Moadab","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2024.107544_bib262","article-title":"Role of the CCL2-CCR2 axis in cardiovascular disease: pathogenesis and clinical implications","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2024.107544_bib263","doi-asserted-by":"crossref","DOI":"10.1038\/sj.jid.5700827","article-title":"Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft","volume":"127","author":"Gazzaniga","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.phrs.2024.107544_bib264","doi-asserted-by":"crossref","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107544_bib265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02759","article-title":"More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis","volume":"10","author":"Gschwandtner","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2024.107544_bib266","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.49.11.4584-4591.2005","article-title":"TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans","volume":"49","author":"Baba","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2024.107544_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic Steatohepatitis: AURORA Phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2024.107544_bib268","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.1c00373","article-title":"BMS-813160: a potent CCR2 and CCR5 dual antagonist selected as a clinical candidate","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107544_bib269","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.730","article-title":"Nivolumab and a CCR2\/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: results of phase I study","volume":"41","author":"Christenson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107544_bib270","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2024.107544_bib271","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.697586","article-title":"Therapeutic peptides targeting PPI in clinical development: overview, mechanism of action and perspectives","volume":"8","author":"Cabri","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.phrs.2024.107544_bib272","unstructured":"Novo Nordisk Annual Report (2023). \u3008https:\/\/www.novonordisk.com\/investors\/annual-report.html\u3009 (Accessed November 25, 2024)."},{"key":"10.1016\/j.phrs.2024.107544_bib273","unstructured":"Mordor Intelligence, Peptide Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029). \u3008https:\/\/www.mordorintelligence.com\/industry-reports\/peptide-therapeutics-market\u3009 (Accesed November 25, 2024)."},{"key":"10.1016\/j.phrs.2024.107544_bib274","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/sj.leu.2404357","article-title":"The pleiotropic effects of the SDF-1\u2013CXCR4 axis in organogenesis, regeneration and tumorigenesis","volume":"20","author":"Ratajczak","year":"2006","journal-title":"Leukemia"},{"issue":"6955","key":"10.1016\/j.phrs.2024.107544_bib275","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01874","article-title":"Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL","volume":"425","author":"Staller","year":"2003","journal-title":"Nature"},{"issue":"32","key":"10.1016\/j.phrs.2024.107544_bib276","doi-asserted-by":"crossref","first-page":"22899","DOI":"10.1074\/jbc.M113.449926","article-title":"CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak","volume":"288","author":"Kremer","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2024.107544_bib277","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.phrs.2024.107544_bib278","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3324\/haematol.2014.120295","article-title":"Differential hypoxic regulation of the microRNA-146a\/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy","volume":"100","author":"Spinello","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2024.107544_bib279","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00404-021-06137-0","article-title":"Overexpression of TGF-\u03b21 and SDF-1 in cervical cancer-associated fibroblasts promotes cell growth, invasion and migration","volume":"305","author":"Xiao","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"issue":"6","key":"10.1016\/j.phrs.2024.107544_bib280","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(18)30147-5","article-title":"Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial","volume":"19","author":"Pernas","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2024.107544_bib281","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154732","article-title":"Cancer immunotherapy focusing on the role of interleukins: a comprehensive and updated study","volume":"249","author":"Samadi","year":"2023","journal-title":"Pathol., Res. Pract."},{"issue":"2","key":"10.1016\/j.phrs.2024.107544_bib282","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40487-018-0089-z","article-title":"The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice","volume":"6","author":"Litmanovich","year":"2018","journal-title":"Oncol. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2024.107544_bib283","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107544_bib284","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"37","key":"10.1016\/j.phrs.2024.107544_bib285","doi-asserted-by":"crossref","first-page":"22338","DOI":"10.1074\/jbc.M115.661074","article-title":"Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum","volume":"290","author":"Nata","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2024.107544_bib286","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41375-018-0290-y","article-title":"IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective \u03b3-chain cytokines, decreases leukemic T-cell viability","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.phrs.2024.107544_bib287","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.2022017643","article-title":"Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia","volume":"142","author":"Brammer","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2024.107544_bib288","article-title":"Immune profiling in patients with glioblastoma treated with VT1021 in a phase I\/II expansion study","volume":"41","author":"Chen","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107544_bib289","first-page":"291","article-title":"THBS1 (thrombospondin-1)","volume":"24","author":"Isenberg","year":"2020","journal-title":"Atlas Genet. Cytogenet. Oncol. Haematol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107544_bib290","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s43856-024-00433-x","article-title":"First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors","volume":"4","author":"Mahalingam","year":"2024","journal-title":"Commun. Med."},{"issue":"2","key":"10.1016\/j.phrs.2024.107544_bib291","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.molcel.2004.11.049","article-title":"Regulation of p21(WAF1\/CIP1) stability by WISp39, a Hsp90 binding TPR protein","volume":"17","author":"Jascur","year":"2005","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.phrs.2024.107544_bib292","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1210\/en.2008-0168","article-title":"A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling","volume":"149","author":"McKeen","year":"2008","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2024.107544_bib293","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/0008-5472.CAN-09-2515","article-title":"FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy","volume":"70","author":"McKeen","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2024.107544_bib294","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/ATVBAHA.114.304539","article-title":"FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis","volume":"35","author":"Yakkundi","year":"2015","journal-title":"Arterioscler.\u00a0Thromb.\u00a0Vasc. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107544_bib295","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/1078-0432.CCR-10-2241","article-title":"FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism","volume":"17","author":"Valentine","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107544_bib296","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41416-022-01780-z","article-title":"A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours","volume":"127","author":"El Helali","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.phrs.2024.107544_bib297","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-13-0595","article-title":"Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway","volume":"19","author":"McClements","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107544_bib298","article-title":"The anti-tumour efficacy of the novel peptide inhibitor of angiogenesis ALM201","author":"O'Rourke","year":"2024","journal-title":"Almac. Discov."},{"issue":"2","key":"10.1016\/j.phrs.2024.107544_bib299","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/jcb.21409","article-title":"Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma","volume":"103","author":"Zhao","year":"2008","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.phrs.2024.107544_bib300","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1074\/jbc.M508386200","article-title":"A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells","volume":"281","author":"S\u00e4fholm","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107544_bib301","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/bs.ircmb.2014.10.003","article-title":"Insight into the role of Wnt5a-induced signaling in normal and cancer cells","volume":"314","author":"Endo","year":"2015","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2024.107544_bib302","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0083-6729(01)63003-6","article-title":"Mechanism of GnRH receptor signaling on gonadotropin release and gene expression in pituitary gonadotrophs","volume":"63","author":"Shacham","year":"2001","journal-title":"Vitam. Horm."},{"issue":"10","key":"10.1016\/j.phrs.2024.107544_bib303","first-page":"830","article-title":"Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer","volume":"27","author":"Van Poppel","year":"2020","journal-title":"Int. J. Urol.\u00a0Off. J. Jpn. Urol. Assoc."},{"issue":"3","key":"10.1016\/j.phrs.2024.107544_bib304","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756287211414457","article-title":"An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer","volume":"3","author":"Boccon-Gibod","year":"2011","journal-title":"Ther. Adv. Urol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107544_bib305","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/pros.21169","article-title":"Ozarelix, a fourth-generation GnRH antagonist, induces apoptosis in hormone-refractory androgen receptor-negative prostate cancer cells modulating expression and activity of death receptors","volume":"70","author":"Festuccia","year":"2010","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.phrs.2024.107544_bib306","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jcla.1860030302","article-title":"Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer","volume":"3","author":"Fekete","year":"1989","journal-title":"J. Clin. Lab. Anal."},{"issue":"9","key":"10.1016\/j.phrs.2024.107544_bib307","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/pros.23360","article-title":"Discovery of LHRH and development of LHRH analogs for prostate cancer treatment","volume":"77","author":"Schally","year":"2017","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.phrs.2024.107544_bib308","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/1535-7163.MCT-18-0770","article-title":"GnRH-R-targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition","volume":"18","author":"Ma","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"8_ement","key":"10.1016\/j.phrs.2024.107544_bib309","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1158\/1538-7445.AM2012-2829","article-title":"Abstract 2829: activity of EP-100 in Non-Hodgkin's Lymphoma - synergy in combination","volume":"72","author":"Leuschner","year":"2012","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2024.107544_bib310","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00345-018-2185-y","article-title":"Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement","volume":"36","author":"Shore","year":"2018","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107544_bib311","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1053\/j.gastro.2019.01.190","article-title":"P120 BBT-401 is a selective Pellino-1 protein-protein interaction inhibitor in clinical development targeting a first-in-class drug for UC treatment","volume":"156","author":"Lee","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.phrs.2024.107544_bib312","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00280-020-04040-0","article-title":"The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats","volume":"85","author":"Mayo","year":"2020","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:49:04Z","timestamp":1736430544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824004894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":312,"alternative-id":["S1043661824004894"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107544","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107544"}}